CONSHOHOCKEN, Pa., July 21, 2026 (GLOBE NEWSWIRE) -- Madrigal Pharmaceuticals, Inc. (NASDAQ:MDGL), a

CONSHOHOCKEN, Pa., July 16, 2026 (GLOBE NEWSWIRE) -- Madrigal Pharmaceuticals, Inc. (Nasdaq: MDGL) a

New U.S. Rezdiffra patents in F2/F3 to be listed in FDA’s Orange BookU.S. Patent No. 12,667,575, dir

Received two new U.S. Rezdiffra ® (resmetirom) patents in F2/F3; both patents will be listed in the

These three biotechs are posting strong revenue growth. Brand-new launches and label expansions shou

CONSHOHOCKEN, Pa., July 06, 2026 (GLOBE NEWSWIRE) -- Madrigal Pharmaceuticals, Inc. (NASDAQ:MDGL), a

/PRNewswire/ -- Suzhou Ribo Life Science Co., Ltd. (06938.HK) y su filial Ribocure Pharmaceuticals A

SUZHOU, China and MÖLNDAL, Sweden, July 1, 2026 /PRNewswire/ -- Suzhou Ribo Life Science Co., Ltd. (

CONSHOHOCKEN, Pa., June 22, 2026 (GLOBE NEWSWIRE) -- Madrigal Pharmaceuticals, Inc. (NASDAQ:MDGL), a

All three could become highly prominent biotech companies within 10 years.

B of A Securities analyst Alexandria Hammond maintains Madrigal Pharmaceuticals (NASDAQ:MDGL) wit

Madrigal Pharmaceuticals, Inc. (MDGL) Presents at Goldman Sachs 47th Annual Global Healthcare Confer

Madrigal (MDGL) reported earnings 30 days ago. What's next for the stock?

CONSHOHOCKEN, Pa., June 04, 2026 (GLOBE NEWSWIRE) -- Madrigal Pharmaceuticals, Inc. (NASDAQ: MDGL),

CONSHOHOCKEN, Pa., June 03, 2026 (GLOBE NEWSWIRE) -- Madrigal Pharmaceuticals, Inc. (NASDAQ: MDGL) t

Madrigal Pharmaceuticals, Inc. is a high-risk/high-reward play, focused solely on MASH with its firs

Growing body of clinical and real-world evidence supports the role of Rezdiffra® (resmetirom) as the

Growing body of clinical and real-world evidence supports the role of Rezdiffra ® (resmetirom) as th

CONSHOHOCKEN, Pa., May 21, 2026 (GLOBE NEWSWIRE) -- Madrigal Pharmaceuticals, Inc. (NASDAQ:MDGL), a

Secondary analysis from the Phase 3 MAESTRO-NASH and MAESTRO-NAFLD-1 trials examines improvements in

Truist Securities analyst Srikripa Devarakonda maintains Madrigal Pharmaceuticals (NASDAQ:MDGL) w

Canaccord Genuity analyst Edward Nash maintains Madrigal Pharmaceuticals (NASDAQ:MDGL) with a Buy

CONSHOHOCKEN, Pa., May 07, 2026 (GLOBE NEWSWIRE) -- Madrigal Pharmaceuticals, Inc. (NASDAQ:MDGL), a

MDGL stock up on better-than-expected first-quarter results on account of robust Rezdiffra sales, dr

Evercore ISI Group analyst Liisa Bayko maintains Madrigal Pharmaceuticals (NASDAQ:MDGL) with a Ou

Madrigal Pharmaceuticals, Inc. (MDGL) Q1 2026 Earnings Call Transcript

HC Wainwright & Co. analyst Andrew S. Fein reiterates Madrigal Pharmaceuticals (NASDAQ:MDGL)

Madrigal Pharmaceuticals (NASDAQ:MDGL) reported quarterly losses of $(3.25) per share which beat the

- Precision approach targets patients who have a mutation in the PNPLA3 gene, which is highly preval

Company advances its leadership in MASH with clinical-stage, genetically targeted siRNA asset from A

John Paulson's hedge fund discloses the purchase of 9,000 shares of Alphabet.

Stocks That Hit 52-Week Lows On Wednesday

Stocks That Hit 52-Week Lows On Thursday